Clinical trial with "R-75" strain live, attenuated, serum inhibitor-resistant intranasal influenza B vaccine.
AUTOR(ES)
Spencer, M J
RESUMO
The "R-75" strain live, attenuated, serum inhibitor-resistant influenza B vaccine was administered intranasally by drops in two doses 14 days apart to 21 volunteers. Each vaccinee was paired with a close associate (roommate or workmate) who similarly received two doses of a placebo solution. Although about 50% of both vaccine and placebo recipients complained of symptoms after dosage, the severity of symptoms was greater in vaccine recipients. Fourfold serum hemagglutination-inhibiting antibody titer rises occurred in 38% of vaccine recipients, and four vaccines had fourfold titer rises of nasal hemagglutination-inhibiting antibody. Vaccine virus was isolated from three asymptomatic vaccine recipients. There was no virological or serological evidence of the vaccine virus spreading to placebo recipients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=274660Documentos Relacionados
- Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
- Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults
- Some characteristics of a urease-negative, temperature- sensitive strain of Bordetella bronchiseptica as a live, attenuated vaccine.
- Evaluation of a live, attenuated recombinant influenza vaccine in high school children.
- Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.
